158 related articles for article (PubMed ID: 11005777)
21. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes.
Duhaut P; Bosshard S; Calvet A; Pinede L; Demolombe-Rague S; Dumontet C; Loire R; Seydoux D; Ninet J; Pasquier J; Aymard M
J Rheumatol; 1999 Feb; 26(2):361-9. PubMed ID: 9972970
[TBL] [Abstract][Full Text] [Related]
22. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.
Weyand CM; Hicok KC; Hunder GG; Goronzy JJ
Ann Intern Med; 1994 Oct; 121(7):484-91. PubMed ID: 8067646
[TBL] [Abstract][Full Text] [Related]
23. Vertebrobasilar ischemia and structural abnormalities of the vertebral arteries in active temporal arteritis and polymyalgia rheumatica--an ultrasonographic case-control study.
Pfadenhauer K; Esser M; Berger K
J Rheumatol; 2005 Dec; 32(12):2356-60. PubMed ID: 16331763
[TBL] [Abstract][Full Text] [Related]
24. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.
Roche NE; Fulbright JW; Wagner AD; Hunder GG; Goronzy JJ; Weyand CM
Arthritis Rheum; 1993 Sep; 36(9):1286-94. PubMed ID: 8216422
[TBL] [Abstract][Full Text] [Related]
25. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries.
Schmidt WA; Gromnica-Ihle E
Rheumatology (Oxford); 2002 Jan; 41(1):46-52. PubMed ID: 11792879
[TBL] [Abstract][Full Text] [Related]
26. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
[TBL] [Abstract][Full Text] [Related]
27. Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis.
van Sleen Y; Wang Q; van der Geest KSM; Westra J; Abdulahad WH; Heeringa P; Boots AMH; Brouwer E
Sci Rep; 2017 Jul; 7(1):6553. PubMed ID: 28747747
[TBL] [Abstract][Full Text] [Related]
28. Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis.
Uddhammar AC
Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S32-3. PubMed ID: 10948757
[TBL] [Abstract][Full Text] [Related]
29. Increased 67gallium uptake among polymyalgia rheumatica patients. Is it additional evidence of its vasculitic nature?
Reitblat T; Ben-Horin CL; Reitblat A
Rheumatol Int; 2006 Sep; 26(11):1010-3. PubMed ID: 16596379
[TBL] [Abstract][Full Text] [Related]
30. Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis.
Meyer O; Nicaise P; Moreau S; de Bandt M; Palazzo E; Hayem G; Chazerain P; Labarre C; Kahn MF
Rev Rhum Engl Ed; 1996 Apr; 63(4):241-7. PubMed ID: 8738442
[TBL] [Abstract][Full Text] [Related]
31. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients.
Myklebust G; Gran JT
Scand J Rheumatol; 2001; 30(5):260-7. PubMed ID: 11727839
[TBL] [Abstract][Full Text] [Related]
32. Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis.
Narváez J; Nolla-Solé JM; Narváez JA; Clavaguera MT; Valverde-García J; Roig-Escofet D
Ann Rheum Dis; 2001 Nov; 60(11):1060-3. PubMed ID: 11602480
[TBL] [Abstract][Full Text] [Related]
33. Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis.
Narváez J; Bernad B; Díaz Torné C; Momplet JV; Montpel JZ; Nolla JM; Valverde-García J
J Rheumatol; 2006 Jul; 33(7):1293-8. PubMed ID: 16783861
[TBL] [Abstract][Full Text] [Related]
34. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94.
Gran JT; Myklebust G
J Rheumatol; 1997 Sep; 24(9):1739-43. PubMed ID: 9292797
[TBL] [Abstract][Full Text] [Related]
35. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
[TBL] [Abstract][Full Text] [Related]
36. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
Kyle V; Cawston TE; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):667-71. PubMed ID: 2782977
[TBL] [Abstract][Full Text] [Related]
37. Polymyalgia rheumatica and temporal arteritis: the endocrine relations and the pathogenesis. Review.
Imrich R; Bosak V; Rovensky J
Endocr Regul; 2006 Sep; 40(3):83-9. PubMed ID: 17100550
[TBL] [Abstract][Full Text] [Related]
38. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
[TBL] [Abstract][Full Text] [Related]
39. Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.
Pountain GD; Keogan MT; Brown DL; Hazleman BL
Ann Rheum Dis; 1993 Oct; 52(10):730-3. PubMed ID: 8257209
[TBL] [Abstract][Full Text] [Related]
40. [Polymyalgia rheumatica and temporal arteritis. Observations on prognosis and treatment].
Auquier L; Paolaggi JB
Bull Acad Natl Med; 1990 Feb; 174(2):263-70; discussion 270-3. PubMed ID: 2372721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
